Исследование доказало, что результаты клинических тестов на ходьбу при болезни Паркинсона не отражают реальную мобильность пациентов

A study published today in npj Parkinson's Disease brings quantitative weight to something many patients have long tried to explain to their neurologists: the Parkinson's disease symptoms that produce poor scores on clinic walking tests and the symptoms that keep them sitting at home are not the same thing. The finding, from researchers at Sapienza University of Rome, Université Grenoble Alpes, Kiel University, and the Institut Universitaire de France, carries immediate consequences for how patients are assessed, how treatments are evaluated, and how clinical trial outcome measures are designed. More than 11 million people worldwide are living with Parkinson's disease, with nearly 90,000 new cases diagnosed in the United States each year. Every one of those patients eventually faces the clinical mobility assessment — the supervised walk down the hospital corridor, the timed turn, the scored balance test. Those tests are trusted, standardized, and taught in medical schools. The new research suggests they are also, in a meaningful way, answering a different question than the one that matters most to patients navigating a kitchen, a grocery store, or a flight of stairs. When What Doctors See Is Not What Patients Live The study enrolled 105 people with mild-to-moderate Parkinson's disease in a cross-sectional design. Participants completed a battery of standardized supervised mobility tests — forward walking, backward walking, and turning — while also wearing a consumer smartwatch for five consecutive days to record average daily step counts in their homes and communities. Validated clinical scales captured motor and non-motor symptoms across the cohort. The researchers applied robust multivariable regression to identify which symptom clusters predicted each type of mobility measure. The results drew a sharp boundary between the two worlds. In the clinical setting, tremor-dominant and postural instability/gait disorder (PIGD) subscores predicted supervised mobility performance — the classic motor hallmarks that neurologists have long tracked, and that most treatment decisions are built around. These are the symptoms visible during a clinic visit: the shuffling step, the slowed turn, the balance impairment that appears on a timed test. But average daily step count — the measure of what patients actually do when no one is watching — was predicted by something different: the akinetic-rigid symptom subtype, executive dysfunction, and fatigue. A patient might perform adequately on a supervised walking test yet spend most of their waking hours sedentary, driven not by the severity of their tremor or their balance problem, but by a bone-deep tiredness and a cognitive slowing that no timed corridor walk is designed to capture. What a Smartwatch Measures That a Clinic Cannot The technical distinction between the two measurement approaches is what makes the finding rigorous rather than anecdotal. Supervised clinical tests — the 10-meter walk, the Timed Up and Go, the backward walking battery — capture what rehabilitation scientists and the World Health Organization's International Classification of Functioning (ICF) formally call capacity: the individual's ability to perform a task in a standardized, controlled setting. A trained clinician watches, the environment is controlled, and the patient implicitly understands they are being evaluated. Clinical assessments do not reflect real-world mobility — only continuous tracking of movement patterns and physical activity during daily life offers insight into how patients walk beyond clinical settings. Consumer smartwatches measure something categorically different: performance, meaning the movement activity that actually happens in the patient's own environment across the full span of their days. The five-day step-count approach used in this study is technically distinct from research-grade multi-sensor systems that require multiple body-worn devices with high-frequency sampling — an important practical advantage. Prior research by members of the same team established smartwatch step-count reliability across Parkinson's disease phenotypes, stages, and severities, validating this measurement approach before applying it to clinical inference. Consumer smartwatch step detection works through accelerometers and gyroscopes that detect the periodic wrist-movement patterns associated with walking gait, counting cycles to compute daily steps. A known limitation in PD research is that these algorithms — trained on typical population gait — can undercount steps at the slower, shuffling speeds characteristic of bradykinesia. That constraint is precisely why confirming the measurement's reliability in PD populations before building clinical inferences on it matters. Fatigue and Executive Dysfunction: The Hidden Motor Perhaps the most clinically striking finding concerns what drives real-world ambulatory activity. Among non-motor symptoms, executive dysfunction and fatigue emerged as the primary determinants of mobility across both supervised and real-world measures. This is not fatigue in the colloquial sense of tiredness after exertion. Fatigue in Parkinson's disease has a specific neurological character — a pervasive, often treatment-resistant symptom involving dopaminergic and serotonergic dysfunction in the basal ganglia and limbic circuits. It can manifest as a profound reluctance to initiate movement — not physical inability, but a neurochemical suppression of the motivation and energy to begin. Current guidelines note that clear pharmacological recommendations for managing PD-related fatigue remain limited, with physical interventions and optimized dopaminergic treatment as the primary tools available. Executive dysfunction — difficulty with planning, sequencing, and cognitive flexibility — adds a further layer. In Parkinson's, this emerges from frontostriatal dopamine pathway depletion that links the prefrontal cortex and striatum. About half of Parkinson's patients experience frontostriatal-mediated executive deficits including impaired attention and slowed cognitive processing. These are the cognitive functions that underlie the decision to get up and walk to the next room. When they are impaired, the physics of walking may be preserved while the behavioral initiation that precedes it is not. The akinetic-rigid motor subtype's emergence as a predictor of daily step count is also notable. The akinetic-rigid subtype — characterized by bradykinesia, rigidity, and postural instability rather than tremor — is already associated with poorer prognosis and cognitive decline at higher rates than the tremor-dominant subtype. Its emergence as a real-world ambulatory predictor aligns with the known worse functional trajectory of this group — and implies that daily step-count monitoring may be most critical precisely for the patients at highest long-term risk. Why the Clinical Picture Can Be Misleading The capacity/performance gap is not new to rehabilitation theory — it was formalized in the WHO's International Classification of Functioning in 2001. What is new is the empirical demonstration, in a Parkinson's-specific population, that the two constructs are being driven by different symptom clusters altogether. In research settings, mobility is typically assessed across brief functional walking tasks in supervised environments, capturing capacity rather than performance — and most existing supervised assessments such as the MDS-UPDRS Part III do not directly assess the impact of symptoms on everyday mobility. This matters in the consulting room. A neurologist who reviews a mobility assessment showing adequate walking performance may not recognize the patient sitting across from them as someone whose fatigue and cognitive sluggishness have substantially reduced their ambulatory activity between appointments. The prior research record had already hinted at this: earlier analyses established that clinic walks don't predict home walking, with researchers calling on clinicians to consider employing digital health technology to directly capture patient walking performance. The Bianchini et al. study goes further by identifying which specific symptoms create the divergence. Implications for Clinical Trials The implications extend well beyond individual clinical encounters. Parkinson's disease clinical trials commonly use supervised motor assessments — most often the MDS-UPDRS Part III — as their primary outcome endpoints. Upcoming platform trials, including the UK EJS ACT-PD trial, the French NS-Park Master trial, and Norwegian MAMS trials, still use MDS-UPDRS as primary outcomes with digital endpoints as exploratory measures. If those assessments systematically miss the non-motor drivers of real-world functional limitation — and the current study provides specific evidence that they do — then a trial enrolling patients whose fatigue and executive dysfunction severely limit their daily mobility could produce motor-scale results that look promising while the functional outcome that actually matters to the patient remains unmoved. Conversely, an intervention that specifically targets fatigue or frontostriatal executive function might produce genuine improvements in daily walking without registering meaningfully on a supervised motor endpoint. There is currently limited consensus on the best statistical approach for modeling the complex interplay between real-world digital mobility outcomes and clinical outcomes, and understanding whether such outcomes can predict clinically meaningful changes remains an essential gap in the field. A lack of consensus on which digital biomarkers reflect Parkinson's progression well enough to serve as pivotal trial endpoints has been documented in the systematic review literature. The current study does not resolve that debate, but it provides a specific, empirical reason why the debate matters: the construct captured by standard clinical mobility scales is not the same construct captured by daily step count, and they are driven by different symptom profiles. Consumer Tech as Clinical Infrastructure The use of a consumer-grade smartwatch rather than a research-grade multi-sensor rig in this study is itself an argument. Research-grade PD monitoring systems have historically required multi-sensor synchronized body rigs — sensors placed on the chest, wrists, and feet — that create adherence challenges, particularly for patients with cognitive impairment, and that generate data volumes requiring specialized analysis pipelines. A single consumer smartwatch worn on the wrist for five days approaches the practicality bar required for routine clinical deployment. Treatment adjustments in Parkinson's disease are often based on clinical evaluations at single time points, which are insufficient to adequately assess real-life motor fluctuations — wearable accelerometry continuous real-world monitoring may offer a reliable, objective diagnostic method to assess symptoms and fluctuations as they actually occur. The trajectory toward clinical adoption is real, though slow: NICE in the UK has conditionally recommended five specific wearable systems for remote monitoring to inform treatment decisions, but adoption in routine clinical practice remains limited by clinician acceptance, reimbursement, and the absence of standardized protocols. What Comes Next The study's authors conclude that their findings support a fundamental rethinking of how mobility is assessed in Parkinson's disease — not an either/or choice between clinical tests and wearables, but a genuine requirement for both. The complex interplay between motor and non-motor symptoms warrants multidimensional mobility assessment as a standard of care. For patients and caregivers, the message is more immediate: the fatigue, the brain fog, and the reluctance to move are not secondary complaints to be mentioned in the last minutes of a clinic visit. They are, the data now show, the primary barriers to walking. Naming them, tracking them, and treating them as first-tier clinical concerns is not a matter of managing expectations — it is a matter of measuring the right thing. Study reference: Bianchini E, Petit P, Rinaldi D, et al. Motor and non-motor symptoms impact on different domains of capacity- and performance-related mobility measures in Parkinson's disease. npj Parkinsons Dis. (2026). DOI: 10.1038/s41531-026-01522-5 Frequently Asked Questions Why does a Parkinson's patient sometimes walk well in the clinic but struggle at home? Clinical mobility tests measure what researchers call "capacity" — the ability to perform a task under optimal, supervised conditions. Real-world walking is a measure of "performance" — what actually happens in daily life. According to the new study published August 14, 2026 in npj Parkinson's Disease, these two constructs are driven by different symptom clusters. Clinical scores are predicted by tremor and postural instability — the classic motor symptoms a neurologist scores during an exam. But daily step count is predicted by fatigue, executive dysfunction, and the akinetic-rigid symptom profile. A patient may briefly summon the capacity for a timed walk while spending most of their day too fatigued or cognitively slowed to initiate movement spontaneously. How does fatigue affect walking in Parkinson's disease, and can it be treated? Parkinson's fatigue is neurological in origin — it arises partly from dopaminergic and serotonergic dysfunction in the basal ganglia and limbic circuits, not simply from physical exertion. It can manifest as a suppression of motivation to initiate movement, which is why it reduces daily walking even when motor function is relatively preserved. Treatment options remain limited: current guidelines from the German Society of Neurology and the International Parkinson and Movement Disorder Society primarily recommend optimized dopaminergic therapy and physical exercise interventions, with no established pharmacological treatment specifically approved for PD-related fatigue. Does this study mean that clinical mobility tests in Parkinson's disease are worthless? No — but it does mean they are measuring a specific construct (capacity) that does not capture the full picture of functional life. Clinical tests remain valuable for tracking motor symptom progression, guiding medication adjustments, and detecting physical deterioration. What the study demonstrates is that they are not sufficient on their own to assess how mobile a patient actually is in their daily environment. The authors' recommendation is multidimensional assessment — clinical tests plus wearable-based real-world monitoring — rather than replacement. If clinical trials for Parkinson's treatments use clinic-based motor tests as primary endpoints, what does this finding mean for trial results? It means those trials may be evaluating a construct — supervised motor capacity — that is driven by different symptoms from those driving the real-world functional outcome that matters most to patients. A therapy that significantly reduces fatigue or improves executive function could produce genuine daily-life benefits in walking while appearing relatively unimpressive on a supervised motor endpoint. Conversely, a treatment that improves supervised walking scores without addressing fatigue or cognitive function may look effective in a trial while producing little change in what patients actually do at home. Major upcoming Parkinson's platform trials are beginning to incorporate digital real-world endpoints as exploratory measures, but no regulatory consensus on using daily step count or equivalent performance measures as primary trial endpoints has yet been established. ⓒ 2026 TECHTIMES.com All rights reserved. Do not reproduce without permission.